After 16 years of research and clinical testing, a School of Medicine diabetes expert has authored a book detailing how people with pre-diabetes or type 2 diabetes can manage their condition without the need for weight loss, insulin, medication or supplements.
A new UVA Health study reveals that calls to poison centers involving liver injuries from medications, supplements, alcohol, and other substances surged nearly 400% between 2000 and 2024. Acetaminophen was the leading cause, with suspected suicide the most common reason for exposure. Alcohol ranked second, with cases rising during the COVID-19 pandemic. Over 80% of cases required inpatient care.
UVA Health researchers have discovered how postoperative delirium may trigger dementia in older patients and identified a potential drug to reverse the underlying brain changes. The study found that anesthesia, surgery, and intensive care stress alter gene activity in aged brains, disrupting memory and sleep regulation. Vorinostat, an FDA-approved cancer drug, reversed many of these harmful changes in mice.
UVA researchers discovered how an unhealthy gut may help breast cancer spread – and how an existing drug could potentially stop it.
New research from the UVA Department of Surgery’s Tsung Research Group, published in JAMA Network Open and selected as an Editor’s Pick, provides a national evaluation of real-world use of histotripsy for liver tumors.
On August 4, 2026, the UVA Paul and Diane Manning Institute of Biotechnology hosted its inaugural SPARK Tank competition, bringing together a dynamic mix of faculty, including from the School of […]
GET THE STORIES BEHIND THE RESEARCH
Receive updates about the discoveries, researchers, and ideas shaping our world — straight from UVA.
Modeled after the reality show where entrepreneurs pitch investors, some of UVA’s top researchers are seeking funding for life-changing medical breakthroughs.
The bacterium that causes tuberculosis is shielded by a protective outer membrane that makes the disease difficult to treat. UVA researchers helped identify chemical features that allow drugs to breach that defense.
Qnovia, Inc., a clinical-stage pharmaceutical company, today announced it has secured a worldwide exclusive license to an innovative antimicrobial peptide from the University of Virginia Licensing & Ventures Group. The license marks Qnovia’s expansion into a second major therapeutic area, complementing its lead smoking cessation program as the company pursues breakthrough solutions to population-scale health challenges.
UVA Health researchers have found that gliomas, the most common primary brain tumors in adults, may be more receptive to focused ultrasound drug delivery than normal brain tissue.
A UVA neurologist explains what global transient amnesia is, and what remains a mystery.
A University of Virginia School of Medicine scientist has received a $6.5 million grant to develop the “lymphatic medicine exam of the future” to improve care for chronic swelling, known as lymphedema, and other lymphatic diseases.